e-learning
resources
Vienna 2003
Sunday 28.09.2003
Work-related COPD - Organic dusts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA)
L. A. Kolodkina, T. P. Ses, L. N. Novikova, G. P. Orlova (St Petersburg, Russia)
Source:
Annual Congress 2003 - Work-related COPD - Organic dusts
Session:
Work-related COPD - Organic dusts
Session type:
Thematic Poster Session
Number:
816
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. A. Kolodkina, T. P. Ses, L. N. Novikova, G. P. Orlova (St Petersburg, Russia). Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA). Eur Respir J 2003; 22: Suppl. 45, 816
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
The circulating metabolome in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Markers of inflammation and pulmonary function (PF) in sarcoidosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 313s
Year: 2002
Progressive fibrotic phenotype in exogenous toxic alveolitis (ETA)
Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease
Year: 2020
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Idiopathic pulmonary fibrosis (IPF)
Source: ERS Course 2016
Year: 2016
Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features
Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases
Year: 2017
The study of C5a complement component in patients with idiopathic pulmonary fibrosis, toxic fibrosing alveolitis and extrinsic allergic alveolitis
Source: Eur Respir J 2001; 18: Suppl. 33, 108s
Year: 2001
Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept